Storia in 7 fonti

Vertex Sees Over $5 Billion Peak Sales Potential From Crinetics Assets - Vertex Pharmaceuticals (NASDAQ:V

Vertex to acquire Crinetics for $10 billion, adding approved acromegaly drug Palsonify and late-stage CAH candidate atumelnant to its rare disease portfolio.

Raccontata da

markets.businessinsider.com

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo1 mese fa

Vertex Sees Over $5 Billion Peak Sales Potential From Crinetics Assets - Vertex Pharmaceuticals (NASDAQ:V

Vertex to acquire Crinetics for $10 billion, adding approved acromegaly drug Palsonify and late-stage CAH candidate atumelnant to its rare disease portfolio.

originale

Timeline cronologica

lunedì 6 luglio 2026·markets.businessinsider.com
M&A News: Vertex Stock (VRTX) Slips After Announcing the $10B Crinetics Acquisition
Vertex Pharmaceuticals (VRTX) fell about 2.3% after hours on Monday following a deal to acquire endocrine‑focused drugmaker Crinetics Pharmaceut...
lunedì 6 luglio 2026·endpoints.news
Breaking: Vertex makes $10B deal for commercial endocrinology biotech Crinetics
Vertex Pharmaceuticals acquires Crinetics Pharmaceuticals for $10B ($85/share), gaining acromegaly drug Palsonify and endocrinology pipeline with ~$5B peak sales potential.

Vertex Sees Over $5 Billion Peak Sales Potential From Crinetics Assets - Vertex Pharmaceuticals (NASDAQ:V

Confronto fonti

Vertex Sees Over $5 Billion Peak Sales Potential From Crinetics Assets - Vertex Pharmaceuticals (NASDAQ:V

Timeline cronologica

M&A News: Vertex Stock (VRTX) Slips After Announcing the $10B Crinetics Acquisition

Breaking: Vertex makes $10B deal for commercial endocrinology biotech Crinetics

M&A News: Vertex Stock (VRTX) Slips After Announcing the $10B Crinetics Acquisition

Vertex to acquire Crinetics in $10B foray into endocrine disease drugs

Breaking: Vertex makes $10B deal for commercial endocrinology biotech Crinetics

Vertex, in its largest-ever deal, acquires endocrine disease specialist Crinetics for $10B

Vertex Makes A $10 Billion Deal; Biotech Stock Doubles

Crinetics Pharmaceuticals Stock Doubles After The Close: Here's Why - Crinetics Pharmaceuticals (NASDAQ:C

Vertex Makes A $10 Billion Deal; Biotech Stock Doubles

Vertex acquires Crinetics Pharmaceuticals for $10 billion as biotech M&A booms

Vertex to acquire Crinetics in $10B foray into endocrine disease drugs

Vertex, in its largest-ever deal, acquires endocrine disease specialist Crinetics for $10B

Vertex Sees Over $5 Billion Peak Sales Potential From Crinetics Assets - Vertex Pharmaceuticals (NASDAQ:V

Pharmalittle: We’re reading about a $10 billion Vertex deal, the pace of FDA drug approvals, and more

Vertex's $10B Crinetics deal marks its clearest step yet toward biopharma's top ranks